Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co EBIT per Share

The EBIT per Share of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 29, 2026 is -0.07 CNY. In the previous year, EBIT per Share was -0.19 CNY — a change of -63.80% (higher).

EBIT per Share

-0.07CNY

YoY

-63.80%

Last updated:

EBIT per Share of Shanghai Fudan Forward S&T Co is 2025 -0.07 CNY. EBIT per Share of Shanghai Fudan Forward S&T Co was 2024 -0.19 CNY. It decreases by -63.80% higher compared to the previous year.

The Shanghai Fudan Forward S&T Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
0.09 CNY
Jan 1, 2019
0.08 CNY
Jan 1, 2020
-0.04 CNY
Jan 1, 2021
-0.09 CNY
Jan 1, 2022
0.00 CNY
Jan 1, 2023
-0.00 CNY
Jan 1, 2024
-0.19 CNY
Jan 1, 2025
-0.07 CNY
The Shanghai Fudan Forward S&T Co EBIT per Share history
YEAREBIT per ShareYoY
-0.07CNY-63.80%
-0.19CNY+7,158.60%
-0.00CNY-155.27%
0.00CNY-105.41%
-0.09CNY+130.33%
-0.04CNY-148.93%
0.08CNY-13.75%
0.09CNY+19.61%
0.08CNY+13.87%
0.07CNY-16.59%
0.08CNY+35.55%
0.06CNY-11.51%
0.07CNY-40.78%
0.11CNY+26.08%
0.09CNY+166.81%
0.03CNY+3.78%
0.03CNY-37.63%
0.05CNY-23.92%
0.07CNY+261.61%
0.02CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

EBIT per Share of Shanghai Fudan Forward S&T Co is -0.07 CNY in 2025.

EBIT per Share of Shanghai Fudan Forward S&T Co changed from -0.19 CNY to -0.07 CNY, representing a -63.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Shanghai Fudan Forward S&T Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Shanghai Fudan Forward S&T Co